Variation in Antibiotic Prescription in High-Risk Febrile Neutropenia in Portuguese Hospitals

被引:0
|
作者
Freitas, Marta [1 ]
Andrade, Paulo [2 ,3 ]
Pinto, Ricardo [4 ]
Trigo, Fernanda [4 ]
Azevedo, Ana [1 ,5 ,6 ]
Almeida, Francisco [1 ,2 ,6 ]
机构
[1] Univ Porto, Fac Med, Alameda Prof Hernani Monteiro, P-4200039 Porto, Portugal
[2] Unidade Local Saude Sao Joao, Ctr Epidemiol Hosp, Unidade Prevencao & Controlo Infecao & Resistencia, P-4200319 Porto, Portugal
[3] Unidade Local Saude Sao Joao, Serv Doencas Infecciosas, P-4200319 Porto, Portugal
[4] Unidade Local Saude Sao Joao, Serv Hematol Clin, P-4200319 Porto, Portugal
[5] Unidade Local Saude Sao Joao, Ctr Epidemiol Hosp, P-4200319 Porto, Portugal
[6] Univ Porto, Inst Saude Publ, Lab Invest Integrat & Translac Saude Populac ITR, EPIUnit, P-4050600 Porto, Portugal
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 09期
关键词
febrile neutropenia; high risk; antimicrobial stewardship; survey; guidelines; INFECTIOUS-DISEASES SOCIETY; CLINICAL-PRACTICE GUIDELINE; OUTPATIENT MANAGEMENT; FEVER; RESISTANCE; ONCOLOGY; THERAPY;
D O I
10.3390/antibiotics13090822
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Febrile neutropenia (FN) is a potentially severe entity, particularly in hemato-oncologic patients who have higher incidence of colonization with multidrug-resistant bacteria. Discrepancies among guidelines contribute to divergence in antimicrobial practices. Our objective was to assess the variation of practices in antimicrobial therapy in high-risk FN among Portuguese hematologists. Methods: We conducted a cross-sectional study through the implementation of an online survey, open to all clinical hematologists in the country. To characterize practice patterns regarding critical elements in FN management, three clinical vignettes were designed to describe typical situations where narrow-spectrum empiric antibiotics (vignette 1), short-course therapy (vignette 2) and de-escalation (vignette 3) could be performed. The remaining questions characterized clinical experience, department size, and differentiation and decision-making process regarding FN antibiotic therapy. Results: The survey yielded 31 responses from 11 hospitals across four regions. All respondents opted for empiric narrow-spectrum antibiotics, 22.6% opted for short-course therapy (mostly senior specialists from larger settings) and 35.5% for de-escalation (mostly young specialists). Availability of an FN protocol seemed to favor both approaches. These findings should be complemented by qualitative assessments of barriers to best practices and should support the need for interventions to improve antibiotic use in febrile neutropenia.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Microorganisms isolated from blood cultures in children with cancer and high-risk febrile neutropenia from five hospitals in Santiago, Chile, 2012-2015
    Eliana Maldonado, M.
    Acuna, Mirta
    Alvarez, Ana M.
    Aviles, Carmen L.
    de la Maza, Veronica
    Salgado, Carmen
    Tordecilla, Juan
    Varas, Monica
    Venegas, Marcela
    Villarroel, Milena
    Zubieta, Marcela
    Elena Santolaya, M.
    REVISTA CHILENA DE INFECTOLOGIA, 2018, 35 (02): : 140 - 146
  • [22] Identification of cancer patients at high risk of febrile neutropenia
    Scott, S
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 : S16 - S19
  • [23] Do Children with High-Risk Febrile Neutropenia Require Intravenous Antibiotic Therapy Till Neutrophil Recovery? Results of a Randomized Controlled Trial from India
    Gollamudi, V. R. M.
    Anand, K.
    Agiwale, J.
    Chinnaswamy, G.
    Vora, T.
    Narula, G.
    Prasad, M.
    Moulik, N. Roy
    Dhamne, C.
    Bhat, V.
    Parambil, B.
    Srinivasan, S.
    Banavali, S. D.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S72 - S73
  • [24] Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia:: A multicenter randomized trial
    García-Carbonero, R
    Mayordomo, JI
    Tornamira, MV
    López-Brea, M
    Rueda, A
    Guillem, V
    Arcediano, A
    Yubero, A
    Ribera, F
    Gómez, C
    Trés, A
    Pérez-Gracia, JL
    Lumbreras, C
    Hornedo, J
    Cortés-Funes, H
    Paz-Ares, L
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (01): : 31 - 38
  • [25] Application value of metagenomic next-generation sequencing in hematological patients with high-risk febrile neutropenia
    Wang, Xiao
    Zhang, Huiye
    Zhang, Nan
    Zhang, Shan
    Shuai, Yanrong
    Miao, Xiaojuan
    Liu, Yilan
    Qiu, Ling
    Ren, Shihui
    Lai, Sihan
    Han, Ying
    Yao, Hao
    Zhang, Xupai
    Fan, Fangyi
    Sun, Haoping
    Yi, Hai
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
  • [26] Advances in antibacterial treatment of adults with high-risk febrile neutropenia (vol 78, pg 2109, 2023)
    Contejean, Adrien
    Maillard, Alexis
    Canoui, Etienne
    Kerneis, Solen
    Fantin, Bruno
    Bouscary, Didier
    Parize, Perrine
    Garcia-Vidal, Carolina
    Charlier, Caroline
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (11) : 2784 - 2784
  • [27] Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia
    Koh, A
    Pizzo, PA
    CANCER INVESTIGATION, 2002, 20 (03) : 420 - 433
  • [28] C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms
    Combariza, Juan F.
    Lombana, Milton
    Pino, Luis E.
    Arango, Marcos
    SUPPORTIVE CARE IN CANCER, 2015, 23 (04) : 1009 - 1013
  • [29] C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms
    Juan F. Combariza
    Milton Lombana
    Luis E. Pino
    Marcos Arango
    Supportive Care in Cancer, 2015, 23 : 1009 - 1013
  • [30] High Frequency of Antibiotic Prescription in Children With Undifferentiated Febrile Illness in Kenya
    Hooft, Anneka M.
    Ndenga, Bryson
    Mutuku, Francis
    Otuka, Victoria
    Ronga, Charles
    Chebii, Philip K.
    Maina, Priscillah W.
    Jembe, Zainab
    Lee, Justin
    Vu, David M.
    Mukoko, Dunstan
    LaBeaud, A. Desiree
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E2399 - E2406